Edition:
United Kingdom

Knight Therapeutics Inc (GUD.TO)

GUD.TO on Toronto Stock Exchange

8.43CAD
16 Nov 2018
Change (% chg)

$0.05 (+0.60%)
Prev Close
$8.38
Open
$8.38
Day's High
$8.49
Day's Low
$8.31
Volume
319,818
Avg. Vol
99,433
52-wk High
$8.81
52-wk Low
$7.38

Summary

Name Age Since Current Position

James Gale

68 2017 Independent Chairman of the Board

Samira Sakhia

2017 President, Chief Financial Officer, Director

Jonathan Goodman

48 2013 Chief Executive Officer, Director

Amal Khouri

Vice President - Business Development

Nancy Harrison

2018 Director

Meir Jakobsohn

2015 Director

Robert Lande

54 2013 Independent Director

Sylvie Tendler

2014 Independent Director

Biographies

Name Description

James Gale

Mr. James C. Gale is Independent Chairman of the Board of the Company. Mr. Gale is the founding partner of Signet Healthcare Partners (“Signet”). He is currently the Chairman of the Board of Alpex Pharma S.A. and Teligent Inc., and also serves on the board of directors of Spepharm BV, Bionpharma Inc., CoreRx, Inc., Leon Nanodrugs GmbH, Pharmaceutics International, Inc. and Chr. Olesen Synthesis A/S. Prior to Signet, Mr. Gale worked for Gruntal & Co., LLC (“Gruntal”) as head of principal investment activities and investment banking. Prior to joining Gruntal, he worked for Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co. Mr. Gale holds an M.B.A. from the University of Chicago. Mr. Gale was on the board of directors of Paladin from 2008 to 2014.

Samira Sakhia

Ms. Samira Sakhia, CPA, is President, Chief Financial Officer, Director of the Company. Ms. Sakhia joined Knight as President in August 2016 and assumed the additional responsibility of Chief Financial Officer in October 2017. At Knight., Ms. Sakhia oversees the finance, business development, commercial and scientific affairs teams. Prior to joining Knight, Ms. Sakhia served as the CFO at Paladin from 2001 to 2015. At Paladin, Ms. Sakhia was responsible for the finance, operations, human resources and investor relations functions. During her employment with Paladin, Ms. Sakhia was instrumental in executing in-licensing and acquisition transactions of Canadian and international pharmaceutical products and businesses. In addition, Ms. Sakhia led several M&A and strategic lending transactions as well as equity rounds on the TSX and completed the sale of Paladin to Endo for $3.2 billion. Ms. Sakhia holds an MBA and a Bachelors of Commerce degree from McGill University and is also a Chartered Professional Accountant. Ms. Sakhia serves on the boards of Crescita Therapeutics Inc. and Profound Medical Corporation. In addition, Ms. Sakhia serves on the board of the Montreal Society for the Prevention of Cruelty to Animals, the International Advisory Board of McGill’s Desautels Faculty of Management, and is an independent Board member at the McGill University Health Center.

Jonathan Goodman

Mr. Jonathan Ross Goodman is Chief Executive Officer, Director of the Company. Mr. Goodman founded Knight in February 2014. Prior to Knight, Mr. Goodman was the co-founder, President and CEO of Paladin which was acquired by Endo International (“Endo”) for $3.2 billion in February 2014. Under his leadership, $1.50 invested in Paladin at its founding was worth $151 nineteen years later when Paladin was acquired by Endo. Prior to cofounding Paladin in 1995, Mr. Goodman was a consultant with Bain & Company and also worked in brand management for Procter & Gamble. Mr. Goodman currently serves on the board of directors of Medison Biotech (1995) Ltd. Mr. Goodman holds a B.A. with Great Distinction from McGill University and the London School of Economics with 1st Class Honours. Additionally, Mr. Goodman holds an LL.B. and an M.B.A. from McGill University. In 2016, Mr. Goodman was the co-recipient of Ernst & Young’s Quebec Entrepreneur of the Year Award in Health Sciences.

Amal Khouri

Ms. Amal Khouri is Vice President - Business Development of the Company. Global Business Development and Licensing, Novartis Pharmaceuticals Corporation from 2007-2014.

Nancy Harrison

Ms. Nancy Harrison is Director of the Company. Nancy Harrison is former Co-founder and President of MSI Methylation Sciences, a private venture backed development company with a novel treatment of depression in a Phase II clinical trial. She is a former Partner and Senior Vice President of Ventures West Management Inc. Ms. Harrison spent 13 years with Ventures West leading its life sciences practice in Canada and the U.S. She is one of the most experienced life sciences investors in the Canadian venture capital industry and was instrumental in Ventures West's involvement in the sector and with companies such as Angiotech Pharmaceuticals Inc., AnorMed Inc., Salmedix Inc. and Oncogenix Pharmaceuticals Inc., Celator Pharmaceuticals Inc., and Caprion BioSciences. During her time with Ventures West, the firm grew from approximately $80 million to over $750 million. Ms. Harrison has an undergraduate degree in Engineering from Queen's University and an MBA from McGill University.

Meir Jakobsohn

Mr. Meir Jakobsohn is Director of the Company. Mr. Jakobsohn is the CEO of Israeli-based Medison Pharma Ltd. (“Medison”) which he founded in 1996 and spearheaded to becoming a leading international marketing group. Formerly, he served as the Chief Operating Officer of M. Jakobsohn Ltd., a pioneer in opening the Israeli market to global pharmaceutical companies like Ciba-Geigy (Novartis), which it represented between 1937 and 1995. Mr. Jakobsohn holds a B.A. in Economics from Bar-Ilan University and an Executive M.B.A. from Bradford University in the UK.

Robert Lande

Mr. Robert N. Lande is Independent Director of the Company. Mr. Lande is the President of FXCM Group LLC, a brokerage firm providing foreign exchange trading services through its electronic platform to clients globally. Formerly, he was Chief Financial Officer of Global Brokerage Inc., a shareholder in FXCM Group LLC. Previously, Mr. Lande was Managing Partner and Chief Operating Officer of Riveredge Capital Partners LLC and prior to that worked for over 16 years within the BCE/Bell Canada group where his last position was Chief Financial Officer of Telecom Américas Ltd., a joint venture between Bell Canada International, AT&T (then SBC Communications) and America Movil. Mr. Lande is a Chartered Financial Analyst and holds an M.B.A. from the John Molson School of Business and a B.A. in Economics from McGill University. Mr. Lande was a director of Paladin from 1995 to 2014.

Sylvie Tendler

Ms. Sylvie Tendler is Independent Director of the Company. Ms. Tendler is a leading pharmaceutical market research specialist. In 2001, she founded The Tendler Group, a custom medical marketing research company, which served 12 of the Top 20 global pharmaceutical companies. In 2007, the company was acquired by IntrinsiQ LLC (owned at the time by Accel-KKR). Ms. Tendler stayed through 2010 to oversee the managerial transition following the acquisition. Ms. Tendler has hands-on experience conducting global primary research in Canada, the U.S., the top 5 EU markets, as well as Brazil and Mexico, and has been involved in the development and launch of blockbuster prescription products across several therapeutic categories. Ms. Tendler holds a Master’s degree in International Management from the University of Maryland, and a Financial Management Certificate from Cornell University.

Basic Compensation

Name Fiscal Year Total

James Gale

111,975

Samira Sakhia

437,672

Jonathan Goodman

944,345

Amal Khouri

591,669

Nancy Harrison

--

Meir Jakobsohn

--

Robert Lande

124,647

Sylvie Tendler

107,600
As Of  31 Dec 2017